![]() |
Annual Information Service
Product code
345452
Epiomic Patient Segmentation Database |
Epiomic Patient Segmentation Database |
Published: annual subscription
Black Swan Analysis
|
Finding and properly assessing strong sources of epidemiological data is more important than ever before in the age of evidence-based medicine. At Black Swan Analysis, we ensure that each disease area utilises a multitude of relevant and high-quality sources that are validated using internal and external sources to build an extensive, accurate online database.
The Epiomic™ Database is an evidence-based source for patient populations . Going beyond basic prevalence or incidence, patient populations are segmented according to biomarkers, clinical parameters and/or co-morbid conditions.
By providing more detailed segmentation, these refined populations provide the fundamental building blocks for more accurate and robust asset valuations and forecasts .
Utilising the latest research, datasets are constructed using a wide variety of sources and reliable tools and techniques, resulting in a strong and defendable analysis of the epidemiology.
The Epiomic™ Database covers a comprehensive range of over 200 prominent and rare diseases, including over 9,500 sub-populations, organised into 15 therapeutic categories. Each category includes all relevant diseases for the therapy area with easy navigation between diseases. The data shows a 10-year adjustable forecast (up to 2100) split by gender and 5-year age cohorts giving a very detailed perspective of each condition's population.
Choose from options such as annual online database subscription, ready-to-use disease reports or completely customised analysis with extensive analyst support.
*Online subscribers have instant access to live data updates. Data reports can be customised and delivered within 24 hours of request depending on the level of customisation requested. Delivery of fully custom analysis depends on scope but tends to be within 3-4 weeks.
The EpiomicTM Database provides global coverage to make business decisions clear .
A minimum of 85% of indications are covered for 27 major global markets
This is a live database and is updated regularly.